PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $73,050,120 | -13.7% | 1,892,000 | +18.8% | 1.27% | -13.3% |
| Q3 2022 | $84,678,000 | +145.3% | 1,592,000 | +168.9% | 1.47% | +144.0% |
| Q2 2022 | $34,514,000 | -13.7% | 592,000 | +13.0% | 0.60% | -22.1% |
| Q1 2022 | $39,992,000 | -49.3% | 524,000 | -60.1% | 0.77% | -40.2% |
| Q4 2021 | $78,943,000 | +50.6% | 1,312,000 | +40.2% | 1.29% | +45.5% |
| Q3 2021 | $52,416,000 | +28.5% | 936,000 | -12.7% | 0.89% | -60.2% |
| Q1 2019 | $40,800,000 | +80.2% | 1,072,000 | +47.5% | 2.23% | +29.0% |
| Q1 2018 | $22,636,000 | +51.2% | 726,671 | +121.5% | 1.73% | +15.9% |
| Q4 2017 | $14,973,000 | +38.5% | 328,000 | +13.9% | 1.49% | +17.2% |
| Q3 2017 | $10,814,000 | -16.3% | 288,000 | -28.0% | 1.27% | -58.3% |
| Q4 2016 | $12,920,000 | +40.9% | 400,000 | +49.3% | 3.06% | +3.8% |
| Q3 2016 | $9,171,000 | – | 268,000 | – | 2.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |